Literature DB >> 28356529

Antigenic Drift Defines a New D4 Subgenotype of Measles Virus.

Miguel Ángel Muñoz-Alía1, Claude P Muller2, Stephen J Russell3,4.   

Abstract

The measles virus hemagglutinin (MeV-H) protein is the main target of protective neutralizing antibodies. Using a panel of monoclonal antibodies (MAbs) that recognize known major antigenic sites in MeV-H, we identified a D4 genotype variant that escapes neutralization by MAbs targeting the neutralizing epitope (NE) antigenic site. By site-directed mutagenesis, L249P was identified as the critical mutation disrupting the NE in this genotype D4 variant. Forty-two available D4 genotype gene sequences were subsequently analyzed and divided into 2 groups according to the presence or absence of the L249P MeV-H mutation. Further analysis of the MeV-N gene sequences of these 2 groups confirmed that they represent clearly definable, sequence-divergent D4 subgenotypes, which we named subgenotypes D4.1 and D4.2. The subgenotype D4.1 MeVs were isolated predominantly in Kenya and Ethiopia, whereas the MAb-resistant subgenotype D4.2 MeVs were isolated predominantly in France and Great Britain, countries with higher vaccine coverage rates. Interestingly, D4.2 subgenotype viruses showed a trend toward diminished susceptibility to neutralization by human sera pooled from approximately 60 to 80 North American donors. Escape from MAb neutralization may be a powerful epidemiological surveillance tool to monitor the evolution of new MeV subgenotypes.IMPORTANCE Measles virus is a paradigmatic RNA virus, as the antigenic composition of the vaccination has not needed to be updated since its discovery. The vaccine confers protection by inducing neutralizing antibodies that interfere with the function of the hemagglutinin protein. Viral strains are indistinguishable serologically, although characteristic nucleotide sequences differentiate 24 genotypes. In this work, we describe a distant evolutionary branch within genotype D4. Designated subgenotype D4.2, this virus is distinguishable by neutralization with vaccine-induced monoclonal antibodies that target the neutralizing epitope (NE). The subgenotype D4.2 viruses have a higher predominance in countries with intermediary levels of vaccine coverage. Our studies demonstrate that subgenotype D4.2 lacks epitopes associated with half of the known antigenic sites, which significantly impacts our understanding of measles virus evolution.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  antibody-mediated neutralization; antigenic variation; immune evasion; measles virus genotypes; measles virus hemagglutinin; viral epitopes; virus evolution

Mesh:

Substances:

Year:  2017        PMID: 28356529      PMCID: PMC5432853          DOI: 10.1128/JVI.00209-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  80 in total

1.  Resistance of recent measles virus wild-type isolates to antibody-mediated neutralization by vaccinees with antibody.

Authors:  M Klingele; H K Hartter; F Adu; W Ammerlaan; W Ikusika; C P Muller
Journal:  J Med Virol       Date:  2000-09       Impact factor: 2.327

2.  Selection and characterization of human respiratory syncytial virus escape mutants resistant to a polyclonal antiserum raised against the F protein.

Authors:  Lorena Tomé; Sandra Frabasile; Claudia Candia; Alvaro Pittini; Natalia Farina; José Antonio Melero; Juan Arbiza
Journal:  Arch Virol       Date:  2012-03-14       Impact factor: 2.574

3.  Measles virus nomenclature update: 2012.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2012-03-02

4.  Global routine vaccination coverage, 2014.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2015-11-13

5.  Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies.

Authors:  R S van Binnendijk; M C Poelen; G van Amerongen; P de Vries; A D Osterhaus
Journal:  J Infect Dis       Date:  1997-03       Impact factor: 5.226

6.  A hemagglutinin-derived peptide-vaccine ignored by virus-neutralizing passive antibodies, protects against murine measles encephalitis.

Authors:  K C El Kasmi; D Theisen; N H Brons; W Ammerlaan; M Klingele; A T Truong; C P Muller
Journal:  Vaccine       Date:  1999-05-14       Impact factor: 3.641

7.  Two case studies of modified measles in vaccinated physicians exposed to primary measles cases: high risk of infection but low risk of transmission.

Authors:  Jennifer S Rota; Carole J Hickman; Sun Bae Sowers; Paul A Rota; Sara Mercader; William J Bellini
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

8.  Measles virus genetic evolution throughout an imported epidemic outbreak in a highly vaccinated population.

Authors:  Miguel Ángel Muñoz-Alía; Rafael Fernández-Muñoz; José María Casasnovas; Rebeca Porras-Mansilla; Ángela Serrano-Pardo; Israel Pagán; María Ordobás; Rosa Ramírez; María Luisa Celma
Journal:  Virus Res       Date:  2014-11-20       Impact factor: 3.303

9.  Outbreak of measles among persons with prior evidence of immunity, New York City, 2011.

Authors:  Jennifer B Rosen; Jennifer S Rota; Carole J Hickman; Sun B Sowers; Sara Mercader; Paul A Rota; William J Bellini; Ada J Huang; Margaret K Doll; Jane R Zucker; Christopher M Zimmerman
Journal:  Clin Infect Dis       Date:  2014-02-27       Impact factor: 9.079

Review 10.  Measles virus glycoprotein complex assembly, receptor attachment, and cell entry.

Authors:  C K Navaratnarajah; V H J Leonard; R Cattaneo
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

View more
  11 in total

Review 1.  Measles, the need for a paradigm shift.

Authors:  Emilie Javelle; Philippe Colson; Philippe Parola; Didier Raoult
Journal:  Eur J Epidemiol       Date:  2019-10-17       Impact factor: 8.082

2.  Laboratory methods supporting measles surveillance in Queensland, Australia, 2010-2017.

Authors:  Jamie L McMahon; Judith A Northill; Mitchell Finger; Michael Lyon; Stephen B Lambert; Ian M Mackay
Journal:  Access Microbiol       Date:  2020-01-27

3.  Hemagglutinin-specific neutralization of subacute sclerosing panencephalitis viruses.

Authors:  Miguel Ángel Muñoz-Alía; Claude P Muller; Stephen J Russell
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

4.  Probing Morbillivirus Antisera Neutralization Using Functional Chimerism between Measles Virus and Canine Distemper Virus Envelope Glycoproteins.

Authors:  Miguel Angel Muñoz-Alía; Stephen J Russell
Journal:  Viruses       Date:  2019-07-27       Impact factor: 5.048

5.  Bornaviruses in naturally infected Psittacus erithacus in Portugal: insights of molecular epidemiology and ecology.

Authors:  Marlene Cavaleiro Pinto; Hélder Craveiro; Jonas Johansson Wensman; Júlio Carvalheira; Mikael Berg; Gertrude Thompson
Journal:  Infect Ecol Epidemiol       Date:  2019-11-06

6.  MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.

Authors:  Miguel Ángel Muñoz-Alía; Rebecca A Nace; Alexander Tischer; Lianwen Zhang; Eugene S Bah; Matthew Auton; Stephen J Russell
Journal:  PLoS Pathog       Date:  2021-02-03       Impact factor: 6.823

7.  Serotypic evolution of measles virus is constrained by multiple co-dominant B cell epitopes on its surface glycoproteins.

Authors:  Miguel Ángel Muñoz-Alía; Rebecca A Nace; Lianwen Zhang; Stephen J Russell
Journal:  Cell Rep Med       Date:  2021-03-30

8.  Complete Genomic Sequence of Canine Distemper Virus from an Ethiopian Wolf.

Authors:  Denise A Marston; Jemma Watson; Emma L Wise; Richard J Ellis; Eric Bedin; Girma Ayalew; Muktar Abute; Xavier de Lamballerie; Anthony R Fooks; Claudio Sillero-Zubiri; Ashley C Banyard
Journal:  Genome Announc       Date:  2017-07-20

9.  Case-based surveillance of measles in Sicily during 2012-2017: The changing molecular epidemiology and implications for vaccine strategies.

Authors:  Fabio Tramuto; Carmelo Massimo Maida; Fanny Pojero; Giuseppina Maria Elena Colomba; Alessandra Casuccio; Vincenzo Restivo; Francesco Vitale
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

Review 10.  Animal and human RNA viruses: genetic variability and ability to overcome vaccines.

Authors:  T G Villa; Ana G Abril; S Sánchez; T de Miguel; A Sánchez-Pérez
Journal:  Arch Microbiol       Date:  2020-09-28       Impact factor: 2.552

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.